Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and ante-natal care solutions. It offers its products through wholesale drug distributors, and stockiest and retail pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.

Revenue projections:

Revenue projections for ERIS
Revenue projections for ERIS

Investors are expected to be cautious with Eris Lifesciences Limited, as its revenues are projected to fall compared to last year. A decline in revenue often results in a negative impact on profitability, prompting concerns about the company's financial stability and making investors more conservative in their approach.

Financial Ratios:

currentRatio 0.91400
forwardPE 29.52729
debtToEquity 68.18500
earningsGrowth 0.31100
revenueGrowth 0.06900
grossMargins 0.74773
operatingMargins 0.27733
trailingEps 30.45000
forwardEps 41.65000

ERIS's Forward PE being in a good range suggests that its stock price is aligned well with earnings. The stock is not considered overpriced, offering room for future growth, which makes it an appealing investment opportunity with the potential for value appreciation.
With positive gross and operating margins, ERIS demonstrates strong profitability. This reflects the company's ability to manage costs and maintain healthy profits, showcasing effective operational efficiency and financial stability.
ERIS's forward EPS being higher than its trailing EPS signals anticipated growth in profitability for the current financial year. This suggests that ERIS is on track to improve its earnings, outpacing the previous year's performance and reflecting positive market expectations.

Price projections:

Price projections for ERIS
Price projections for ERIS

The price of ERIS has consistently been close to the lower limit of expectations. This trend may point to challenges in the company's performance, leading to concerns about its future growth potential.

Recommendation changes over time:

Recommendations trend for ERIS
Recommendations trend for ERIS


The analysts' recent buy bias for Eris Lifesciences Limited indicates strong confidence in the stock's future performance. This could encourage more investors to view Eris Lifesciences Limited as a worthwhile investment, positioning the company as a top choice for those seeking financial security and long-term growth opportunities.